LEADER 02699nam 2200397 450 001 9910647496303321 005 20230330232008.0 035 $a(CKB)5680000000300312 035 $a(NjHacI)995680000000300312 035 $a(EXLCZ)995680000000300312 100 $a20230330d2022 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aCOVID-19 drug development $erecent advances, new perspectives and applications /$fedited by Arli Aditya Parikesit 210 1$aLondon :$cIntechOpen,$d[2022] 210 4$dİ2022 215 $a1 online resource (166 pages) $cillustrations 311 $a1-80356-989-1 311 $a1-80356-990-5 320 $aIncludes bibliographical references. 327 $a1. Introductory Chapter: Current Perspective of COVID-19 Drugs 22 -- 2. Pluralism Medical Treatment, Prevention, and Control of COVID-19 Infection and Its Long-Sufferings among the Older Adults in the Northeast of Thailand from 2019 to 2022 142 -- 3. Baricitinib in the Treatment of COVID-19 53 -- 4. New Perspective and Applications of Homeopathy in Treating COVID-19 Symptoms 28 -- 5. Treatments for the Infection by SARS-CoV-2 49 -- 6. Inclusive Review on Existing Treatment and Management Modalities for COVID-19 39 -- 7. COVID-19: From Pathophysiology to Treatment 35 -- 8. COVID-19 Drug Development: Role of Drug Repurposing 16. 330 $aCOVID-19 is a rampant worldwide problem. It is caused by the SARS-CoV-2 virus and is manifest in different variants. The Delta variant compromised existing therapeutic and preventive options for this disease and is beginning to be replaced by the Omicron variant. Through pharmaceutical biotechnology, three different treatment approaches to COVID-19 have been developed: computer-aided drug design (CADD); rational drug design in the wet lab; and the advanced drug delivery system. These approaches are heavily influenced by advances in life sciences, such as the development of structural bioinformatics, the establishment of nanobiotechnology as a standard approach in drug design, and major advances in structural biology such as the development of the CryoEM method. This book will focus on providing possible solutions to the ongoing COVID-19 pandemic in light of these advances in life sciences. 517 $aCOVID-19 Drug Development 606 $aCOVID-19 (Disease) 615 0$aCOVID-19 (Disease) 676 $a614.59241 702 $aParikesit$b Arli Aditya 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910647496303321 996 $aCOVID-19 drug development$93086007 997 $aUNINA